Advocacy intelligence hub — real-time data for patient organizations
ARCE Therapeutics, Inc.
Allogene Therapeutics — PHASE1
Instituto de Investigacion Sanitaria INCLIVA — NA
Chongqing Precision Biotech Co., Ltd — PHASE1
Anhui Provincial Hospital — NA
Centre Hospitalier Universitaire de Saint Etienne — PHASE4
Institute of Hematology & Blood Diseases Hospital, China — PHASE1
OHSU Knight Cancer Institute — PHASE2
ARCE Therapeutics, Inc. — PHASE1, PHASE2
The Children's Hospital of Zhejiang University School of Medicine — PHASE1
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
GAVRETO�
(pralsetinib)Orphan drugacceleratedRigel Pharmaceuticals, Inc.
Kinase Inhibitor [EPC]
12.1 Mechanism of Action Pralsetinib is a kinase inhibitor of wild-type RET and oncogenic RET fusions (CCDC6- RET ) and mutations ( RET V804L, RET V80...
He Huang, MD
Zhejiang University
📍 Hanzhou, Zhejiang
Jianhua Mao, PhD
Shanghai Children's Medical Center
📍 Shanghai, Shanghai Municipality
Pablo Tebas, MD
University of Pennaylvania
📍 PHILADELPHIA, PA
David Shook, MD
Nkarta, Inc.
Miles Prince, MD
Peter MacCallum Cancer Center, Melbourne, Australia
Chi Hornik, PharmD
Duke University
📍 DURHAM, NC